M. Scot Roberts - Jan 31, 2022 Form 4 Insider Report for Altimmune, Inc. (ALT)

Signature
/s/ Kent Tapper, as Attorney-in-Fact
Stock symbol
ALT
Transactions as of
Jan 31, 2022
Transactions value $
-$2,973
Form type
4
Date filed
2/3/2022, 06:55 PM
Previous filing
Aug 6, 2021
Next filing
Jun 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Award $14.4K +2.11K +18.14% $6.86 13.7K Jan 31, 2022 Direct F1, F2
transaction ALT Common Stock, par value $0.0001 Options Exercise $0 +6.17K +44.95% $0.00 19.9K Feb 1, 2022 Direct F3
transaction ALT Common Stock, par value $0.0001 Tax liability -$17.4K -2.18K -10.98% $7.98 17.7K Feb 1, 2022 Direct F4
holding ALT Common Stock, par value $0.0001 15 Jan 31, 2022 Shares held by spouse of Reporting Person

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Restricted Stock Units Options Exercise $0 -6.17K -25% $0.00 18.5K Feb 1, 2022 Common Stock, par value $0.0001 6.17K Direct F3, F5
transaction ALT Stock Options (option to buy) Award $0 +91.6K $0.00 91.6K Feb 2, 2022 Common Stock, par value $0.0001 91.6K $7.53 Direct F6
transaction ALT Restricted Stock Units Award $0 +31.1K $0.00 31.1K Feb 2, 2022 Common Stock, par value $0.0001 31.1K Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2021 through January 31, 2022.
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2022.
F3 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F4 Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F5 The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
F6 Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date.
F7 The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.